Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Monday, Benzinga reports. The brokerage currently has a $170.00 price target on the biotechnology company’s stock.

Several other research firms also recently weighed in on ASND. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Oppenheimer reiterated an “outperform” rating and issued a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Citigroup increased their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, Bank of America increased their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Stock Up 0.4 %

ASND stock opened at $125.77 on Monday. Ascendis Pharma A/S has a 52 week low of $86.54 and a 52 week high of $161.00. The firm has a market capitalization of $7.63 billion, a P/E ratio of -13.62 and a beta of 0.66. The company has a fifty day simple moving average of $133.42 and a two-hundred day simple moving average of $133.56.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -7.24 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of ASND. BNP Paribas Financial Markets grew its holdings in Ascendis Pharma A/S by 4,231.4% during the first quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after acquiring an additional 73,796 shares during the period. FORA Capital LLC purchased a new stake in Ascendis Pharma A/S in the 1st quarter worth approximately $703,000. GSA Capital Partners LLP acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $992,000. SG Americas Securities LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at approximately $288,000. Finally, ProShare Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 9.9% in the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 361 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.